We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

71 hedge funds and large institutions have $356M invested in Repare Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

62,533% more call options, than puts

Call options by funds: $1.88M | Put options by funds: $3K

0% more funds holding

Funds holding: 7171 (0)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

1.09% less ownership

Funds ownership: 79.36%78.27% (-1.1%)

12% less capital invested

Capital invested by funds: $403M → $356M (-$47.1M)

25% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 24

Holders
71
Holders Change
Holders Change %
0%
% of All Funds
1.22%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
11
Increased
18
Reduced
24
Closed
11
Calls
$1.88M
Puts
$3K
Net Calls
+$1.88M
Net Calls Change
-$598K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$101M
DTC
2
Deep Track Capital
Connecticut
$37.9M +$5.41M +420,005 +16%
CA
3
CHI Advisors
New York
$37.2M +$5.45M +423,066 +16%
RG
4
Redmile Group
California
$32.6M -$471K -36,600 -1%
AIM
5
ARK Investment Management
Florida
$31.9M -$1.9M -147,303 -5%
MAM
6
MPM Asset Management
Massachusetts
$27.2M
T. Rowe Price Investment Management
7
T. Rowe Price Investment Management
Maryland
$21.4M +$22.7M +1,762,743 New
MB
8
MPM BioImpact
Massachusetts
$19.9M
AG
9
Artal Group
Luxembourg
$8.49M
BlackRock
10
BlackRock
New York
$4.98M -$33.4K -2,591 -0.6%
Citadel Advisors
11
Citadel Advisors
Florida
$3.8M +$2.22M +172,256 +122%
HS
12
HighVista Strategies
Massachusetts
$3.69M +$1.95M +151,581 +99%
Millennium Management
13
Millennium Management
New York
$3M +$2.1M +163,126 +194%
Sumitomo Mitsui Trust Group
14
Sumitomo Mitsui Trust Group
Japan
$2.27M +$2.41M +187,037 New
NAMA
15
Nikko Asset Management Americas
New York
$2.15M +$2.41M +187,037 New
Fidelity Investments
16
Fidelity Investments
Massachusetts
$2.15M -$15.4M -1,198,158 -87%
Morgan Stanley
17
Morgan Stanley
New York
$1.79M -$5.59K -434 -0.3%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.64M -$589K -45,779 -25%
UBS AM
19
UBS AM
Illinois
$1.48M -$237K -18,429 -13%
Ensign Peak Advisors
20
Ensign Peak Advisors
Utah
$1.1M +$70.5K +5,480 +6%
TI
21
Trexquant Investment
Connecticut
$966K +$366K +28,447 +56%
Vanguard Group
22
Vanguard Group
Pennsylvania
$895K +$7.72K +600 +0.8%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$793K -$114K -8,857 -12%
Mirae Asset Global Investments
24
Mirae Asset Global Investments
South Korea
$729K +$773K +60,068 New
State Street
25
State Street
Massachusetts
$649K +$8.34K +648 +1%

RPTX Hedge Fund Activity: Q3 2022 in Review

71 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q3 2022, worth a combined $356M — down 12% from $403M a quarter earlier.

Fund positioning in RPTX was balanced in Q3 2022: 11 funds opened new positions, 11 closed out, 18 added to existing stakes and 24 trimmed.

The largest buyer was CHI Advisors, adding an estimated $5.45M. The largest seller was T. Rowe Price Associates, cutting an estimated $24.7M.

  • 71 institutional investors held Repare Therapeutics (RPTX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $356M of Repare Therapeutics stock for Q3 2022, down 12% quarter-over-quarter.
  • 11 funds opened new Repare Therapeutics positions in Q3 2022 and 11 closed out, a net change of 0 holders.
  • The largest Repare Therapeutics buyer in Q3 2022 was CHI Advisors, an estimated $5.45M added.
  • The largest Repare Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $24.7M sold.

Based on aggregated 13F filings for Q3 2022.